Clene’s cash, cash equivalents and marketable securities totaled $49.2 million as of June 30, 2023, compared to $23.3 million as of December 31, 2022. Clene expects that its resources as of June 30, 2023, will be sufficient to fund its operations through mid-2024.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CLNN:
- Clene Reports Second Quarter 2023 Financial Results and Operating Highlights
- Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference
- Clene price target lowered to $5 from $7 at Benchmark
- Insiders Pour Millions Into These 2 ‘Strong Buy’ Stocks — Here’s Why You Might Want to Steer Toward Them Too
- Clene announces publication of Phase 2 CNM-Au8 clinical data